Sarilumab对比标准治疗早期干预COVID-19肺炎住院患者:SARTRE随机对照试验方案结构化摘要
SARTRE是一项在西班牙多中心开展的2期、开放标签、平行对照随机试验,计划纳入200例重症COVID-19住院患者,按1:1随机接受sarilumab联合甲泼尼龙及标准治疗,或甲泼尼龙联合标准治疗。主要终点为进展至严重呼吸衰竭、入住ICU或死亡的患者比例。
要点
- 早期使用sarilumab联合糖皮质激素可能阻止COVID-19肺炎进展为呼吸衰竭。
- 纳入标准包括RT-PCR阳性、影像学浸润、SpO2≤94%需氧疗及炎症指标升高。
- 主要终点为进展至严重呼吸衰竭、ICU入住或死亡的复合比例。
核心结论
- 旨在评估早期sarilumab联合标准治疗(含糖皮质激素)是否优于单纯标准治疗,以预防COVID-19间质性肺炎患者进展为呼吸衰竭。
研究设计与样本
- 2期多中心随机对照试验,两个平行组按1:1随机,计划纳入200例重症COVID-19住院患者,每组100例。
- 随机码由SAS PROC PLAN生成,按中心分层,区组长度为2的倍数,通过eCRF隐蔽管理。
- 开放标签设计,所有研究药物均不设盲。
关键数值与推荐
- 纳入标准:年龄≥18岁,RT-PCR阳性,影像学肺浸润或听诊湿啰音,室内空气SpO2≤94%需补充氧气。
- 炎症标准:IL-6 > 40 pg/mL或D-二聚体 >1.0 mcg/ml,或24-48小时内CRP、LDH、血清铁蛋白、淋巴细胞减少或D-二聚体中至少两项进行性恶化。
- 排除标准包括高氧需求(储氧面罩、无创通气、高流量鼻导管或机械通气)、ICU入住、妊娠或哺乳、对sarilumab或糖皮质激素过敏、5个月内免疫抑制抗体治疗、AST/ALT > 10倍正常上限、中性粒细胞< 0.5 x 109/L、严重血小板减少< 50 x 109/L等。
- 干预:实验组接受sarilumab+甲泼尼龙+COVID-19标准治疗;对照组接受甲泼尼龙+标准治疗;所有患者甲泼尼龙剂量为1mg/kg/d至少3天。
- 主要终点:进展至严重呼吸衰竭(Brescia-COVID ≥2)、ICU入住或死亡的患者比例。
临床怎么用
- 对照组患者若进展至Brescia-COVID 2-3伴炎症标志物升高,可选择接受sarilumab补救治疗并进入开放标签阶段。
- 随机分至sarilumab组患者若进展至Brescia-COVID 2-3,按当地临床实践方案进行补救。
- 所有患者在第29天进行最终随访访视。
局限性
- 开放标签设计可能引入偏倚。
- 样本量较小(200例),统计效能有限。
- 研究仅在西班牙多家医院开展,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: In some patients, acute, life-threatening respiratory injury produced by viruses such as SARS-CoV and other viral pneumonia are associated with an over-exuberant cytokine release. Elevated levels of blood IL-6 had been identified as a one of the risk factors associated with severe COVID-19 disease. Anti-IL6 inhibitors are among the therapeutic armamentarium for preventing the fatal consequences of acute respiratory and multi organ failure in around 20% of the COVID-19 infected patients. At present, their use is prioritized to patients with severe interstitial pneumonia (Brescia-COVID Scale-COVID 2-3) with hyperinflammation as determined by the presence of elevated IL6 and/or d-dimer, or progressive d-dimer increase, in patients who otherwise are subsidiary to ICU admission. However, many uncertainties remain on the actual role of anti-IL6 inhibitors in this setting, and whether current use and timing is the right one. There is the hypothesis that the use of anti-IL6 inhibitors at an earlier state during the hyperinflammatory syndrome would be beneficial and may avoid progressing to ARDS. On the other hand, the standard of care has changed and nowadays the use of corticosteroids has become part of the SOC in the treatment of COVID-19 pneumonia. Our limited experience suggests that better treatment outcomes can be achieved when combining IL6-inhibitors (e.g. sarilumab) with corticosteroids. The aim of the present study is to evaluate if an earlier therapeutic intervention with sarilumab plus SOC (including corticosteroids) may be more effective than current standard of care alone, in preventing progression to respiratory failure in COVID-19 infected patients with interstitial pneumonia. This study will also provide supportive evidence to that provided by currently ongoing studies on the efficacy and safety of sarilumab in this clinical context. TRIAL DESIGN: A phase two multi-center randomised controlled trial (RCT) with two parallel arms (1:1 ratio). PARTICIPANTS: They will be hospitalized patients, of at least 18 years of age, with severe COVID-19 who have positive RT-PCR test and have radiographic evidence of pulmonary infiltrates by imaging or rales/crackles on exam and SpO2 ≤ 94% on room air that requires supplemental oxygen. Patients must present elevation of inflammatory parameters (IL-6 > 40 pg/mL or d-dimer >1.0 mcg/ml) or, alternatively, progressive worsening in at least two of these inflammatory parameters in the prior 24-48h: CRP, LDH, serum ferritin, lymphopenia, or d-dimer. EXCLUSION CRITERIA: high oxygen requirements (including face mask with reservoir, non-invasive mechanical ventilation or high flow nasal cannula, or mechanical ventilation), admission to ICU, pregnancy or lactation, allergy or hypersensitivity to sarilumab or corticoesteroids, immunosuppressive antibody therapy within the past 5 months, AST/ALT values > 10 x ULN, neutropenia (< 0.5 x 109/L), severe thrombocytopenia (< 50 x 109/L), sepsis caused by an alternative pathogen, diverticulitis with risk of perforation or ongoing infectious dermatitis. The study will be conducted in several hospitals in Spain. INTERVENTION AND COMPARATOR: Patients randomised to the experimental arm will receive sarilumab + methylprednisolone plus SOC for COVID-19. Patients included in the control arm will receive methylprednisolone plus SOC for COVID-19. Corticosteroids will be given to all patients at a 1mg/kg/d of methylprednisolone for at least 3 days. Clinical follow-up visits will be performed at 3, 5, and 15 days after treatment randomization. Patients in the control group (SOC group without sarilumab) progressing to Brescia- COVID 2-3 plus inflammatory markers, will be given the option to be rescued with sarilumab at the same doses and, in that case, be included in an open-label phase and be followed up for additional weeks (with visits at 3, 7 and 15 days after sarilumab rescue administration). Patients randomly assigned to sarilumab therapy at baseline progressing to Brescia-COVID 2-3 will be rescued according to local clinical practice protocols. A final follow-up visit will be conducted for all patients at day 29 from randomization, regardless of initial treatment assignment. MAIN OUTCOMES: Primary end point is the proportion of patients progressing to either severe respiratory failure (Brescia-COVID ≥2), ICU admission, or death. RANDOMIZATION: Randomization codes were produced by means of the PROC PLAN of the SAS system, with a 1:1 assignment ratio, stratifying by centre and using blocks multiple of 2 elements. The randomization schedule will be managed through the eCRF in a concealed manner. BLINDING (MASKING): All study drugs will be administered as open label. No blinding methods will be used in this trial. NUMBERS TO BE RANDOMISED (SIMPLE SIZE): The target sample size will be 200 COVID-19 patients, who will be allocated randomly to control arm (100) and treatment arm (100). TRIAL STATUS: Protocol Code: SARTRE Protocol Date: May 05th 2020. Version: 2.0 The study has been approved by the Spanish Competent Authority (AEMPS) as a low intervention clinical trial. Start of recruitment: August, 2020 End of recruitment: May, 2021 TRIAL REGISTRATION: Identifier: EudraCT Number: 2020-002037-15 ; Registration date: 26 May 2020. FULL PROTOCOL: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this letter serves as a summary of the key elements of the full protocol. The study protocol has been reported in accordance with the Standard Protocol Items: Recommendations for Clinical Interventional Trials (SPIRIT) guidelines (Additional file 2).
引用
- Caballero Bermejo AF, Ruiz-Antorán B, Fernández Cruz A, et al. Sarilumab versus standard of care for the early treatment of COVID-19 pneumonia in hospitalized patients: SARTRE: a structured summary of a study protocol for a randomised controlled trial. Trials. 2020. PMID: 32938496. doi:10.1186/s13063-020-04633-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。